1 / 18

Spinocerebellar Ataxia and X-Linked Bulbospinal Neuronopathy

Spinocerebellar Ataxia and X-Linked Bulbospinal Neuronopathy. Trinucleotide repeat expansions and other dynamic mutations Roy Poh October 2007. Spinocerebellar Ataxias. Autosomal dominant neurodegenerative disorder Genetically heterogeneous 28 subtypes listed

bern
Download Presentation

Spinocerebellar Ataxia and X-Linked Bulbospinal Neuronopathy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Spinocerebellar Ataxiaand X-Linked Bulbospinal Neuronopathy Trinucleotide repeat expansions and other dynamic mutations Roy Poh October 2007

  2. Spinocerebellar Ataxias • Autosomal dominant neurodegenerative disorder • Genetically heterogeneous • 28 subtypes listed • 9 SCAs are caused by dynamic mutations - SCA1, 2, 3, 6, 7 & 17 - due CAG repeat expansion also referred as polyglutamine disorder. - SCA8 (CTG repeat), SCA10 (ATTCT repeat), SCA12

  3. Molecular genetics of SCAs

  4. Clinical features of SCAs • Characterised by progressive cerebellar ataxia of gait and limbs • With variably associated with extrapyramidal & pyramidal signs, eye movements, deafness, retinopathy, peripheral neuropathy • Disease onset is usually between 30 and 50 (Childhood and adult >60 years old has been reported) • Difficult to classify based on clinical features only

  5. Classification of SCAs • Use as guideline for clinical practise and prioritize genetic tests for diagnosis.

  6. Prevalence • Up to 5-7 in 100,000 in some populations • Frequency varies in population and ethically • Founder effects contribute to variable prevalence in subtypes Worldwide SCA 3 21% SCA 2 15% SCA 6 15% SCA 7 5% SCA 1 6% SCA 8 3% Rare 5% Unknown 30%

  7. Genetics of SCA • Autosomal dominant • CAG repeat expansion vary among disorders - A strong correlation between number of repeats and severity of the disease (larger number of repeats – earlier onset and more severe of the disease) - Mutable normal alleles (intermediate alleles) (Increased risk of disease causing allele in next generation; reduced / full penetrance?) • Anticipation – earlier onset and increase severity in next generation; somatic instability (in larger repeats), SCA7 being most unstable • Repeat expansion outside coding region (5’UTR, Intron, 3’UTR) • Missense mutations

  8. Structure of SCA genes

  9. Genetic tests • Estimated 50 - 60% can be identified (SCA1, 2, 3, 6, 7, 8, 10, 12 , 17 and DRPLA) • Test available not associated with repeat expansions (SCA 5, 13, 14, 27, 16q22-linked SCA) • Test in group – based on broad clinical overlap - eg. Common group - SCA 1, 2, 3, 6 & 7 Follow by - SCA 10, 12, 14 & 17 • PCR Analysis • Southern Blot analysis - SCA 2, 7, 8 & 10 (> 100 CAG repeats) • Individualized testing (eg. specific diagnosis, ethic background and population frequency)

  10. X-Linked Bulbospinal neuronopathy • Kennedy disease / Spinal & Bulbar Muscular Atrophy (SBMA) • Polyglutamine disorder (CAG in exon 1 of Androgen receptor on Xq11-12) • X-linked recessive and affect only males • Few than1:50,000 live male births (Seen Caucasian or Asian but not in African or Aboriginal racial background) • Symptoms begin age 20 to 50 years and not in childhood and adolescence • Mutation in AR gene cause androgen insensitivity syndrome

  11. Clinical Features • Slow progressive neuromuscular disorder • Degeneration of lower motor neuron results in proximal muscle weakness, muscular atrophy and fasiculations. • Affected individuals show gynecomastia, testicular atrophy and reduced fertility as a result of mild androgen insensitivity • Female carriers with expanded CAG usually asymptomatic but muscle cramps and occasional tremors reported

  12. Clinical features (cont) • Often confused with: - Amyotrophic lateral sclerosis (ALS) - 1 in 25 cases - Spinal muscular atrophy type 4 (SMA) - SCA 3 - Friedreich ataxia

  13. Genetic test • PCR amplification of CAG repeat in AR gene • Normal allele: ≤34 CAG repeats • Full penetrance allele: ≥38 CAG repeats • Reduced penetrance allele: 36 - 37 CAG repeats (35 CAG repeats – ?, no consensus) • CAG repeat relatively stable with small length shifts and contractions • Generally repeat length inversely correlates with ages of onset but exceptions have been reported • Genotype/phenotype correlation in 60% of cases

  14. Polyglutamine disorders – Mechanisms • Molecular and cellular events that underlie neurodegeneration is still poorly understood • Mechanisms proposed: - Polyglutamine tract is proteolytically cleavaged releasing toxic fragments and inclusions formation – (except SCA 2 & 6 where found in cytoplasm) - Expanded polyglutamine tract leads to conformational change and aggregation - Expanded polyglutamine tract causes sequestration of cellular factors

  15. Mechanisms (con’t) • Findings indicate Interference with molecular pathways: - Protein aggregation and clearance - Ubiquitin-proteasome system - Transcriptional regulation - Alterations of calcium homeostasis • Pathways could act independently or interact and enhance each others • Leading to neuronal dysfunction and death • Disease causing genes are expressed widely in affected neurons only

  16. Summary: Polyglutamine disorders • SCA1, 2, 3, 6, 7, 17 and SBMA (DRPLA & HD) • CAG repeat in the coding region of the gene • Overlapping Clinical pathological features • SBMA is relatively distinct from SCAs • Encoded proteins are unrelated and without similarity in functions and sub-cellular localisation • Pathogensis linked to polyglutamine expanded tract – causes toxic gain of function but mechanism not completely known

  17. Polyglutamine disorder: Gene and function

  18. Reference • www.geneclinics.org • Autosomal dominant cerebellar ataxia: clinical features, genetics and pathogenesis. Lancet Neurology, 2004, 3, 291-304. • Molecular Pathogeneisis of spinocerebellar ataxia. Brain, 2006, 129, 1357-1370. • Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Human Molecualr Genetics, 2007, 16, 115-123. • Repeats instability: Mechanisms of dynamic mutations. Nature Review Genetics, 2005, 6, 729-742. • Therapeutics development for triplet repeat expansion diseases. 2005, Nature Review Genetics, 6, 756-765.

More Related